Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Still a Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped up prior to trading on Monday . The stock had previously closed at $19.11, but opened at $21.36. Ascentage Pharma Group International shares last traded at $21.0670, with a volume of 5,707 shares trading hands.

Analyst Ratings Changes

A number of analysts have recently issued reports on AAPG shares. Rodman & Renshaw assumed coverage on shares of Ascentage Pharma Group International in a report on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price objective on the stock. Oppenheimer assumed coverage on shares of Ascentage Pharma Group International in a report on Thursday, December 4th. They set an “outperform” rating and a $45.00 target price for the company. Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. Truist Financial set a $51.00 price target on shares of Ascentage Pharma Group International in a research report on Monday, November 24th. Finally, BTIG Research started coverage on shares of Ascentage Pharma Group International in a research note on Thursday, March 12th. They set a “buy” rating and a $48.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company. According to data from MarketBeat.com, Ascentage Pharma Group International presently has an average rating of “Buy” and a consensus price target of $48.00.

Ascentage Pharma Group International Trading Up 11.0%

The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54. The business has a 50 day moving average price of $24.57 and a 200-day moving average price of $30.35.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Ascentage Pharma Group International in the 3rd quarter valued at about $96,000. ABC Arbitrage SA acquired a new position in Ascentage Pharma Group International during the third quarter worth approximately $204,000. Citadel Advisors LLC acquired a new position in Ascentage Pharma Group International during the third quarter worth approximately $383,000. Hsbc Holdings PLC bought a new stake in Ascentage Pharma Group International in the second quarter valued at approximately $391,000. Finally, UBS Group AG lifted its position in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares during the last quarter.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.